Targeting DPPIV with therapeutic inhibitors holds immense promise toward the mitigation of long-term cardiovascular and cerebrovascular risks, particularly in post-COVID-19 fatigue patients with comorbidities that include diabetes and hypertension. The gene discussed is DPP4; the disease is Hypertension.